Successful collaboration with Epithelix in the characterization of AlveolAir™, a new primary 3D human alveolar model designed to advance respiratory virus research and antiviral development.

The study described an innovative in vitro alveolar co-culture system at the air–liquid interface, developed by Epithelix, which maintains human primary alveolar type I and II epithelial and endothelial cells with a functional barrier for over 30 days.
We characterized AlveolAir™ as a relevant system for modelling respiratory infections caused by H1N1 influenza and SARS-CoV-2 viruses by highlighting key differences in their pathophysiological effects and epithelial innate immune responses. Importantly, Baloxavir and Remdesivir significantly reduced viral replication, making AlveolAir™ model a reliable in vitro platform for drug screening.

Virnext and VirPath’s team are delighted to be continuing the long-standing collaboration with Samuel Constant and collaborators at Epithelix in order to improve predictive preclinical in vitro models for infectious disease research, development of new antivirals, and pandemic preparedness.

Read the publication : https://lnkd.in/ehgsd2tM